Novartis Sells Roche Stake for $20.7 Billion, Exiting 20-Year Shareholding

On November 4, Novartis announced that it had signed a $20.7 billion transaction agreement with Roche to sell its Roche stake, which it began acquiring 20 years ago, back to the company.

Novartis and Roche are premier global pharmaceutical giants, both headquartered in Basel, Switzerland, with their corporate offices situated just a few kilometers apart. Yet, the two companies are far more than mere rivals dominating the pharmaceutical industry. In fact, over the past two decades, Novartis has held one-third of Roche’s voting bearer shares. Consequently, rumors of a potential merger between the two, alongside lingering questions regarding their ability to maintain financial independence, have persisted unabated for years.

Currently, Roche is repurchasing these shares for $20.7 billion.

Novartis CEO Vas Narasimhan said in a statement: “After more than 20 years as a Roche shareholder, we have concluded that now is the right time to monetize our investment.”

The returns appear to be quite substantial: As early as 2001, Novartis invested $2.8 billion in cash to acquire a 20% stake in the company, representing 32 million shares at $87 per share. Under the agreement, Novartis will sell its holdings at $388.99 per share, with its current stake having increased to 53.3 million shares. According to Novartis, this will generate approximately $14 billion in proceeds.

On the other hand, Roche plans to cancel the repurchased shares upon completion of the debt financing transaction. The company added that "the dissolution of two competitors" means Roche has "regained full strategic flexibility."

Therefore, the voting rights of the founding family consortium will increase to 67.5%, while the public shareholding will also rise from 16.6% to 24.9%.

Twenty years ago, the unusual entanglement between two pharmaceutical giants shocked investors, leading some analysts to predict that they might merge at some point. However, a major merger never materialized. Instead, Roche acquired Genentech, securing three blockbuster oncology drugs to build its own asset portfolio.

▽Follow 【WuXiGermany】WeChat Official Account